Lenalidomide

ClinicalAugust 15, 2026

Study on Belantamab Mafodotin and Lenalidomide in Newly Diagnosed Multiple Myeloma

A clinical trial is underway to evaluate the efficacy of belantamab mafodotin combined with lenalidomide as maintenance therapy in newly diagnosed multiple myeloma patients post-autologous hematopoietic cell transplantation.

Sponsor company

Mechanism of action

Recent signals(10)

Phase II Trial of Brentuximab Vedotin and Lenalidomide in Relapsed/Refractory T-Cell Lymphoma

Study on Belantamab Mafodotin and Lenalidomide in Newly Diagnosed Multiple Myeloma

FDA Approves Lenalidomide ANDA217554 Submission by Deva Holding AS

FDA Accepts Supplement Application for Lenalidomide by Arrow International

Lenalidomide being studied for treatment of adult histiocyte disorders

FDA Accepts Supplement for Lenalidomide by Biocon Pharma

FDA Accepts Supplement Application for Lenalidomide by Accord Healthcare

FDA Accepts Supplement Application for Lenalidomide by QILU

FDA Acceptance of Lenalidomide Supplement Application by Mylan

Lupin's Lenalidomide ANDA214398 Receives Abbreviated Approval

Upcoming milestones

Related catalysts(6)

— Lenalidomide

— Lenalidomide

— Lenalidomide

— Lenalidomide

— Lenalidomide

— Lenalidomide

Indications

Therapeutic areas

Get signals before the market moves